Ginkgo Bioworks (NYSE:DNA) Posts Quarterly Earnings Results, Beats Estimates By $0.15 EPS

Ginkgo Bioworks (NYSE:DNA – Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($0.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.90) by $0.15, FiscalAI reports. The firm had revenue of $20.16 million during the quarter, compared to the consensus estimate of $24.05 million. Ginkgo Bioworks had a negative return on equity of 56.08% and a negative net margin of 215.41%.

Here are the key takeaways from Ginkgo Bioworks’ conference call:

Get Ginkgo Bioworks alerts:

• Revenue fell sharply: Q2 2026 revenue declined 48% year over year to $20 million, while adjusted EBITDA worsened to negative $36 million from negative $25 million.
• Q2 cash burn increased to $45 million from $38 million a year earlier, and excess leased-space costs rose to $14 million; the company nevertheless reaffirmed full-year 2026 cash-burn guidance of $125 million to $150 million.
• Ginkgo reported progress scaling Nebula, its Boston autonomous lab, to 105 racks and said it is operating 24/7 with roughly 30 unique protocols per day, potentially improving service economics and demonstrating the platform to prospective customers.
• The company announced autonomous-lab awards involving MIT, Caltech, the University of Maryland, and Northwestern, expanding its reach into academic research and potentially supporting future lab-equipment, software, and support revenue.
• Ginkgo said its ADME-One service attracted approximately 16 customers in its first six weeks and offers a drug-screening panel for $199, substantially below quoted Western and Chinese CRO pricing, although the company still needs to establish repeat demand and scale.

Ginkgo Bioworks Price Performance

Shares of DNA stock traded down $0.01 during trading on Wednesday, reaching $9.37. The company had a trading volume of 980,052 shares, compared to its average volume of 870,150. The firm’s 50 day simple moving average is $8.82 and its two-hundred day simple moving average is $8.33. Ginkgo Bioworks has a one year low of $5.37 and a one year high of $17.58. The company has a market capitalization of $611.72 million, a PE ratio of -1.75 and a beta of 1.78.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Wall Street Zen downgraded shares of Ginkgo Bioworks from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ginkgo Bioworks in a research report on Friday, July 17th. One research analyst has rated the stock with a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Reduce” and an average target price of $8.50.

Check Out Our Latest Report on Ginkgo Bioworks

Institutional Trading of Ginkgo Bioworks

Institutional investors have recently made changes to their positions in the business. Millennium Management LLC lifted its position in shares of Ginkgo Bioworks by 113.1% during the 1st quarter. Millennium Management LLC now owns 1,427,600 shares of the company’s stock worth $8,137,000 after buying an additional 757,535 shares during the period. State Street Corp boosted its stake in Ginkgo Bioworks by 38.4% in the fourth quarter. State Street Corp now owns 1,292,071 shares of the company’s stock worth $10,737,000 after purchasing an additional 358,231 shares in the last quarter. Squarepoint Ops LLC bought a new stake in shares of Ginkgo Bioworks during the fourth quarter worth $1,636,000. Tudor Investment Corp ET AL acquired a new stake in shares of Ginkgo Bioworks in the fourth quarter valued at $1,612,000. Finally, Geode Capital Management LLC raised its stake in shares of Ginkgo Bioworks by 23.7% in the fourth quarter. Geode Capital Management LLC now owns 999,600 shares of the company’s stock worth $8,309,000 after acquiring an additional 191,240 shares during the last quarter. 78.63% of the stock is currently owned by institutional investors and hedge funds.

About Ginkgo Bioworks

(Get Free Report)

Ginkgo Bioworks, Inc is a synthetic biology company that designs custom microbes for customers across a range of industries. Utilizing a proprietary organism foundry platform, the company engineers cells to produce high-value chemicals, enzymes, and other biological materials. By integrating automation, data analytics and machine learning, Ginkgo Bioworks seeks to accelerate the development of biologically derived solutions at industrial scale.

The company’s services span the entire development cycle, from genetic design and strain optimization to fermentation and downstream processing.

Featured Articles

• Five stocks we like better than Ginkgo Bioworks
• SpaceX: Love the Company, But the Stock Is a Harder Call
• Ulta’s Growth Is Real, But So Are the Risks
• BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
• Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth

Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.